Bellevue Group’s Immunogen Inc IMGN Stock Holding History

Bellevue Group’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-30,000	Closed	-$256K	–	132
2016 Q1	$256K	Buy	+30,000	New	+$254K	0.05%	119

Other funds holding IMGN

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bellevue Group's IMGN Position: Q2 2016 in Review

Bellevue Group sold out of Immunogen Inc (IMGN) in Q2 2016, closing a stake of 30,000 shares — an estimated $256K sold.

Bellevue Group first reported a position in IMGN in Q1 2016 and held it in 1 quarter. The position peaked at $256K in Q1 2016. 158 funds tracked by Wall St. Rank hold IMGN as of Q2 2016.

Bellevue Group reported no remaining Immunogen Inc position as of Q2 2016 after selling out during the quarter.
Bellevue Group sold 30,000 Immunogen Inc shares in Q2 2016, an estimated $256K.
Bellevue Group first reported a position in Immunogen Inc in Q1 2016 and held it in 1 quarter.
Bellevue Group's Immunogen Inc position peaked at $256K in Q1 2016.
158 funds tracked by Wall St. Rank held Immunogen Inc as of Q2 2016.

Based on Bellevue Group's 13F filing for Q2 2016, filed 12 Aug 2016.